Which of the following medications is a second generation antipsychotic and is also used to treat bipolar disorder and Tourettes syndrome?

Long-term management of Fluoxetine involves maintaining remission of depressive symptoms while preventing relapse. Even when a patient reports sustained improvement and functional recovery, antidepressants are not stopped abruptly due to the risk of symptom recurrence and discontinuation effects. Decisions about stopping therapy require a structured, supervised plan that includes dose tapering and clinical monitoring. Individualized assessment of relapse risk, duration of remission, and history of depressive episodes guides safe discontinuation.

Rationale:
A. Stopping the drug abruptly is unsafe because sudden withdrawal of fluoxetine can lead to discontinuation symptoms such as mood instability, irritability, and sleep disturbances. Although fluoxetine has a long half-life, it still requires careful tapering in many patients. Abrupt cessation also increases the risk of depressive relapse, especially after long-term treatment.

B. A drug holiday is not an evidence-based or safe strategy for antidepressant management. Temporary cessation does not assess true remission and may destabilize neurotransmitter balance, leading to rebound symptoms. This approach may actually trigger a recurrence of depressive symptoms.

C. Discussing gradual withdrawal with the provider is the safest and most appropriate approach. A supervised taper allows monitoring for recurrence of depressive symptoms while minimizing withdrawal effects. The provider can evaluate risk factors and determine whether continued maintenance therapy or stepwise discontinuation is indicated.

D. Indefinite therapy is not universally required for all patients with depression. While some individuals with recurrent or severe depression may need long-term treatment, others in sustained remission may successfully taper off medication under supervision. Treatment duration should be individualized rather than automatically lifelong.

Monoamine oxidase inhibitors (MAOIs) are antidepressants that prevent the breakdown of monoamines such as norepinephrine, serotonin, and dopamine. This leads to increased levels of these neurotransmitters but also creates a risk for hypertensive crisis when certain dietary amines are consumed. Tyramine-rich foods can trigger sudden and severe blood pressure elevations in patients taking MAOIs. Immediate assessment focuses on identifying dietary triggers when hypertension is present.

Rationale:
A. Grapefruit juice is more commonly associated with cytochrome P450 enzyme inhibition, affecting drugs like statins and calcium channel blockers. It is not a primary trigger of hypertensive crisis in patients taking MAOIs. While important in medication safety, it is not the most relevant immediate assessment in this scenario.

B. Antihypertensive medication use is important in general cardiovascular assessment, but it does not explain acute hypertensive spikes specific to MAOI therapy. The sudden elevation in blood pressure is more likely related to dietary interactions rather than baseline antihypertensive control issues.

C. Asking the patient to list all foods eaten that day helps identify ingestion of tyramine-rich foods that can trigger hypertensive crisis in patients taking Monoamine oxidase inhibitors. Foods such as aged cheese, cured meats, fermented products, and certain alcoholic beverages can cause excessive norepinephrine release, leading to dangerous blood pressure elevations. This is the most immediate and relevant assessment.

D. Concurrent use of SSRIs with MAOIs is a serious interaction that can cause serotonin syndrome, but it does not typically present as isolated hypertension. While important to assess medication interactions, the acute hypertensive episode is more consistent with a tyramine reaction rather than serotonergic toxicity.